非洲重症监护或高护病房收治的COVID-19感染患者的医疗护理与临床结局(ACCCOS):一项多中心、前瞻性、观察性队列研究
ACCCOS是一项在非洲10国64家医院开展的多中心、前瞻性、观察性队列研究,纳入2020年5月至12月转诊至重症监护或高护病房的成人(≥18岁)疑似或确诊COVID-19患者。主要终点为入院30天内院内死亡率,共3140例患者参与,30天院内死亡率为48.2%(95%CI 46.4-50.0)。与死亡独立相关的因素包括年龄每增加1岁、HIV/AIDS、糖尿病、慢性肝病、慢性肾病、因资源短缺导致的入院延迟、入院时qSOFA评分、呼吸支持、入院24小时内发生心跳呼吸骤停及需要血管升压药;类固醇治疗与生存相关(OR 0.55)。作者认为非洲重症COVID-19患者死亡率高于亚洲、欧洲、北美和南美报告的研究,死亡率升高与重症监护资源不足、合并症及入院时器官功能障碍严重程度相关。
要点
- 非洲10国64家医院3140例重症COVID-19患者30天院内死亡率为48.2%(95%CI 46.4-50.0;1483/3077)。
- 因资源短缺导致入院延迟与死亡独立相关(OR 2.14;95%CI 1.42-3.22)。
- 有创机械通气与死亡独立相关(OR 15.27;95%CI 8.51-27.37),高流量氧疗(OR 2.72;95%CI 1.46-5.08)和持续气道正压(OR 3.93;95%CI 2.13-7.26)亦与死亡相关。
- 合并HIV/AIDS(OR 1.91;95%CI 1.31-2.79)、糖尿病(OR 1.25;95%CI 1.01-1.56)、慢性肝病(OR 3.48;95%CI 1.48-8.18)、慢性肾病(OR 1.89;95%CI 1.28-2.78)与死亡独立相关。
- 类固醇治疗与生存相关(OR 0.55;95%CI 0.37-0.81),女性性别与结局无关(OR 0.86;95%CI 0.69-1.06)。
适用人群与场景
- 成人(年龄18岁或以上)疑似或确诊COVID-19感染,转诊至重症监护或高护病房者。
- 来自非洲10国(埃及、埃塞俄比亚、加纳、肯尼亚、利比亚、马拉维、莫桑比克、尼日尔、尼日利亚和南非)64家医院。
红旗征与不能漏的情况
- 入院24小时内发生心跳呼吸骤停与死亡独立相关(OR 4.43;95%CI 2.25-8.73)。
- 需要血管升压药与死亡独立相关(OR 3.67;95%CI 2.77-4.86)。
- 入院时qSOFA评分1项因素(OR 1.44;95%CI 1.01-2.04)、2项因素(OR 2.0;95%CI 1.33-2.99)、3项因素(OR 3.66;95%CI 2.12-6.33)与死亡独立相关。
研究设计与关键结果
- 研究类型:多中心、前瞻性、观察性队列研究;注册号ClinicalTrials.gov NCT04367207。
- 2020年5月至12月,6779例患者转诊至重症监护,3752例(55.3%)被收治,来自10国64家医院的3140例(83.7%)患者参与;平均年龄55.6岁;3118例参与者中1890例(60.6%)为男性。
- 医院重症监护医师中位数为2人(IQR 1-4);57家站点中49家(86%)所有患者均可获得脉搏血氧饱和度监测。
- 主要终点:入院30天内院内死亡率为48.2%(95%CI 46.4-50.0;1483/3077例患者)。
- 与死亡独立相关的因素:年龄每增加1岁(OR 1.03;95%CI 1.02-1.04);HIV/AIDS(OR 1.91;95%CI 1.31-2.79);糖尿病(OR 1.25;95%CI 1.01-1.56);慢性肝病(OR 3.48;95%CI 1.48-8.18);慢性肾病(OR 1.89;95%CI 1.28-2.78);因资源短缺导致的入院延迟(OR 2.14;95%CI 1.42-3.22);入院时qSOFA评分1项因素(OR 1.44;95%CI 1.01-2.04)、2项因素(OR 2.0;95%CI 1.33-2.99)、3项因素(OR 3.66;95%CI 2.12-6.33);呼吸支持:高流量氧疗(OR 2.72;95%CI 1.46-5.08)、持续气道正压(OR 3.93;95%CI 2.13-7.26)、有创机械通气(OR 15.27;
- 类固醇治疗与生存相关(OR 0.55;95%CI 0.37-0.81)。
- 女性性别与结局无关(OR 0.86;95%CI 0.69-1.06)。
证据类型、等级与局限
- 证据类型:多中心、前瞻性、观察性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为非洲重症COVID-19患者死亡率高于亚洲、欧洲、北美和南美报告的研究。
- 作者认为死亡率升高与重症监护资源不足、HIV/AIDS、糖尿病、慢性肝病和肾病等合并症以及入院时器官功能障碍严重程度相关。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: There have been insufficient data for African patients with COVID-19 who are critically ill. The African COVID-19 Critical Care Outcomes Study (ACCCOS) aimed to determine which resources, comorbidities, and critical care interventions are associated with mortality in this patient population.
METHODS: The ACCCOS study was a multicentre, prospective, observational cohort study in adults (aged 18 years or older) with suspected or confirmed COVID-19 infection who were referred to intensive care or high-care units in 64 hospitals in ten African countries (ie, Egypt, Ethiopia, Ghana, Kenya, Libya, Malawi, Mozambique, Niger, Nigeria, and South Africa). The primary outcome was in-hospital mortality censored at 30 days. We studied the factors (ie, human and facility resources, patient comorbidities, and critical care interventions) that were associated with mortality in these adult patients. This study is registered on ClinicalTrials.gov, NCT04367207.
FINDINGS: From May to December, 2020, 6779 patients were referred to critical care. Of these, 3752 (55·3%) patients were admitted and 3140 (83·7%) patients from 64 hospitals in ten countries participated (mean age 55·6 years; 1890 [60·6%] of 3118 participants were male). The hospitals had a median of two intensivists (IQR 1-4) and pulse oximetry was available to all patients in 49 (86%) of 57 sites. In-hospital mortality within 30 days of admission was 48·2% (95% CI 46·4-50·0; 1483 of 3077 patients). Factors that were independently associated with mortality were increasing age per year (odds ratio 1·03; 1·02-1·04); HIV/AIDS (1·91; 1·31-2·79); diabetes (1·25; 1·01-1·56); chronic liver disease (3·48; 1·48-8·18); chronic kidney disease (1·89; 1·28-2·78); delay in admission due to a shortage of resources (2·14; 1·42-3·22); quick sequential organ failure assessment score at admission (for one factor [1·44; 1·01-2·04], for two factors [2·0; 1·33-2·99], and for three factors [3·66, 2·12-6·33]); respiratory support (high flow oxygenation [2·72; 1·46-5·08]; continuous positive airway pressure [3·93; 2·13-7·26]; invasive mechanical ventilation [15·27; 8·51-27·37]); cardiorespiratory arrest within 24 h of admission (4·43; 2·25-8·73); and vasopressor requirements (3·67; 2·77-4·86). Steroid therapy was associated with survival (0·55; 0·37-0·81). There was no difference in outcome associated with female sex (0·86; 0·69-1·06).
INTERPRETATION: Mortality in critically ill patients with COVID-19 is higher in African countries than reported from studies done in Asia, Europe, North America, and South America. Increased mortality was associated with insufficient critical care resources, as well as the comorbidities of HIV/AIDS, diabetes, chronic liver disease, and kidney disease, and severity of organ dysfunction at admission.
FUNDING: The ACCCOS was partially supported by a grant from the Critical Care Society of Southern Africa.
参考来源
- Patient care and clinical outcomes for patients with COVID-19 infection admitted to African high-care or intensive care units (ACCCOS): a multicentre, prospective, observational cohort study. Lancet. 2021. PMID: 34022988. doi:10.1016/S0140-6736(21)00441-4
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。